Trial Profile
A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-014; PANACEA
- 11 Feb 2019 Results (Data cut-off: Aug 7, 2017) published in the Lancet Oncology
- 27 Sep 2018 Status changed from active, no longer recruiting to completed.
- 27 Jun 2018 This trial has been completed in Austria (End date: 2018-01-31), according to European Clinical Trials Database.